BR112012018065A2 - "método e usos com relação à identificação de composto envolvido em dor assim como métodos de diagnóstico de algesia" - Google Patents

"método e usos com relação à identificação de composto envolvido em dor assim como métodos de diagnóstico de algesia"

Info

Publication number
BR112012018065A2
BR112012018065A2 BR112012018065A BR112012018065A BR112012018065A2 BR 112012018065 A2 BR112012018065 A2 BR 112012018065A2 BR 112012018065 A BR112012018065 A BR 112012018065A BR 112012018065 A BR112012018065 A BR 112012018065A BR 112012018065 A2 BR112012018065 A2 BR 112012018065A2
Authority
BR
Brazil
Prior art keywords
pain
methods
well
diagnosing
compound involved
Prior art date
Application number
BR112012018065A
Other languages
English (en)
Inventor
Gebauer Mathias
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012018065A2 publication Critical patent/BR112012018065A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

patente de invenção:"métodos e usos com relação à identificação de composto envolvido em dor assim como métodos de diagnóstico de algesia". a presente invenção refere-se a um método de identificação de um composto envolvido em dor, ao uso de ácido nucleico lrrfip 1 ou à proteína lrrfip 1 para identificação de um composto envolvido em dor assim como métodos de diagnóstico de algesia envolvendo os mesmos.
BR112012018065A 2010-01-21 2011-01-20 "método e usos com relação à identificação de composto envolvido em dor assim como métodos de diagnóstico de algesia" BR112012018065A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305069A EP2348130A1 (en) 2010-01-21 2010-01-21 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia
PCT/EP2011/050780 WO2011089194A1 (en) 2010-01-21 2011-01-20 Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia

Publications (1)

Publication Number Publication Date
BR112012018065A2 true BR112012018065A2 (pt) 2019-09-24

Family

ID=42111599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018065A BR112012018065A2 (pt) 2010-01-21 2011-01-20 "método e usos com relação à identificação de composto envolvido em dor assim como métodos de diagnóstico de algesia"

Country Status (13)

Country Link
US (1) US20130053265A1 (pt)
EP (2) EP2348130A1 (pt)
JP (1) JP2013517760A (pt)
KR (1) KR20120123449A (pt)
CN (1) CN102959089A (pt)
AU (1) AU2011208730A1 (pt)
BR (1) BR112012018065A2 (pt)
CA (1) CA2787273A1 (pt)
IL (1) IL220828A0 (pt)
MX (1) MX2012008472A (pt)
RU (1) RU2012135294A (pt)
SG (1) SG182654A1 (pt)
WO (1) WO2011089194A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI963989A (fi) 1996-10-04 1998-04-05 Wallac Oy Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon
GB2377940A (en) * 2001-07-27 2003-01-29 Warner Lambert Co Identification and use of molecules implicated in pain
EP1336661A1 (en) * 2002-02-14 2003-08-20 Biofrontera Pharmaceuticals AG Multiple genes relevant for the characterisation, diagnosis, and manipulation of neuropatic pain
US20030216341A1 (en) * 2002-02-14 2003-11-20 Hermann Lubbert Multiple genes relevant for the characterization, diagnosis, and manipulation of neuropathic pain
WO2005043973A2 (en) * 2003-10-28 2005-05-19 Janssen Pharmaceutica Nv Assay systems and methods for detecting molecules that interact with sk2 channels

Also Published As

Publication number Publication date
CA2787273A1 (en) 2011-07-28
RU2012135294A (ru) 2014-02-27
SG182654A1 (en) 2012-08-30
EP2526206A1 (en) 2012-11-28
JP2013517760A (ja) 2013-05-20
AU2011208730A1 (en) 2012-08-09
MX2012008472A (es) 2012-08-15
US20130053265A1 (en) 2013-02-28
CN102959089A (zh) 2013-03-06
KR20120123449A (ko) 2012-11-08
IL220828A0 (en) 2012-08-30
WO2011089194A1 (en) 2011-07-28
EP2348130A1 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
EA201590027A1 (ru) Способы детекции заболеваний или состояний
CA2865594C (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
BR112014015851A2 (pt) proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
BR112014011594A2 (pt) anticorpos anti-il-36r
BR112015022821A2 (pt) método para avaliar status renal em um indivíduo e kit de ensaio de diagnóstico
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
CL2015000420A1 (es) Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3.
BR112015014900A2 (pt) gel oral compreendendo complexo de zinco-aminoácido
BR112015001327A2 (pt) complexo cristalino de 1-ciano-2-(4-ciclopropil-benzil) -4-(beta-d-glicopiranos-1-il) -benzeno, métodos para sua preparação e o uso do mesmo para preparar medicamentos
BRPI0719879A8 (pt) sal de adição de ácido, processo para sua preparação e seu uso, bem como intermediário químico
EA201491643A1 (ru) Идентификация мутаций канал-опсина-2 (chop2) и способы применения
BR112015004029A2 (pt) Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo
BR112015007196A2 (pt) processos em fase de solução para a fabricação de depsipeptídeos e novos intermediários
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
WO2015014903A3 (en) Diagnostic tools for alzheimer's disease
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
BR112013013522A2 (pt) polinucleotídeo ou um sal deste, composição farmacêutica, uso de um polinucleotídeo ou um sal deste, reagente, composição, e, método para produzir um composto
BR112014027991A2 (pt) agentes para neutralização de influenza
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
BR112013025294A2 (pt) moléculas de ligação biespecífica ligando a dll4 e ang2
BRPI1014222A2 (pt) composto, composição farmacêutica,e, métodos para tratar distúrbio(s) cognitivo(s) ou indicações com déficit(s) na cognição, mal de alzheimer, e distúrbio bipolar
BR112016010159A2 (pt) usos de um conjunto de ácidos nucleicos e de um chip de microarranjo, chip de microarranjo, métodos para detecção de patógenos e/ou microrganismos benéficos em uma amostra orgânica e de tratamento de uma relva doente, e, kit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.